Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BioLineRx of Israel and I-Bridge Capital Form China JV for Drug In-licensing

publication date: Aug 25, 2016
BioLineRx, an Israeli in-licensing company, established a joint venture with I-Bridge Capital, a China VC investor seeking to develop innovative therapies for China. The JV, named iPharma, will look primarily in Israel to license innovative clinical and pre-clinical candidates for China and international markets. BioLineRx has already out-licensed two of its candidates to China companies; it isn't clear if the JV will be BioLineRx's agent in China for additional deals. Each company will invest $1 million in the JV initially. More details....

Stock Symbols: (NSDQ/TASE: BLRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here